INTERVIEW: Bespak Bets On New Drug-Delivery Tech To Help Pharma Overcome Compliance Hurdles
This article was originally published in Clinica
Bespak Europe Ltd. believes its innovative drug-delivery technologies can offer pharma partners an important market differentiator for their drugs, especially viscous drugs injected in high volumes that patients are often reluctant to use.
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.